Recombinant transmembrane domain-deficient sting as biomimetic protein carrier for cgamp enhanced cancer immunotherapy
AssigneeNortheastern University
InventorJiahe Li
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions comprising a fusion protein and a STING agonist, wherein the fusion protein comprises STINGΔTM protein fused to a cell-penetrating domain or a nanobody to deliver STING agonists. Also disclosed are methods of treating cancer, which is achieved by a administering said compositions.
Claims21
A composition, comprising a fusion protein and a STING agonist, wherein the fusion protein comprises STINGΔTM protein fused to a cell-penetrating domain or a nanobody.
A fusion protein, comprising STINGΔTM protein fused to a cell-penetrating domain or a nanobody.
A method of treating cancer or an infectious disease, comprising administering to a patient in need thereof an effective amount of a composition comprising a fusion protein and a STING agonist, wherein the fusion protein comprises STINGΔTM protein fused to a cell-penetrating domain or a nanobody.
-37. (canceled)
Dependencies are inferred from the claim text.